SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
TRANSGENOMIC, INC.
-------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 Par Value
-------------------------------------------------------------
(Title of Class of Securities)
89365K206
-------------------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the filing person: (1) has a previous statement on the
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has no amendment subsequent thereto
reporting beneficial ownership of five percent or less of such class.) (See Rule
13d-7.)
*The remainder of this cover page shall be filled our for a reporting person's
initial filing of this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
This Amendment No. 2 amends and supplements the Statement on Schedule 13G
electronically filed with the Securities and Exchange Commission (the
"Commission") on February 7, 2002, and Amendment No. 1 filed with the Commission
on February 11, 2003 with respect of the ownership of securities of
Transgenomic, Inc. (the "Initial Statement"). Since reporting person now holds
less than 5% with this filing, further reporting under Schedule 13G is no longer
required.
The undersigned hereby amends and supplements Item 6 of the Initial Statement
with the following information (capitalized terms used herein without definition
shall have the same meaning as set forth in the Initial Statement).
(Continued on following page(s))
CUSIP NO. 89365K206 13G
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GlaxoSmithKline plc
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
5 SOLE VOTING POWER
NUMBER OF 1,247,687
SHARES
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY
EACH
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 1,247,687
WITH
8 SHARED DISPOSITIVE POWER
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,247,687
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
[ ]
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.92%
12 TYPE OF REPORTING PERSON*
CO
*SEE INSTRUCTION BEFORE FILLING OUT!
CUSIP NO. 89365K206 13G
Item 1. (a). Name of Issuer:
(b). Address of Issuer's Principal Executive Offices:
Item 2. (a). Names of Person Filing:
(b). Address of Principal Business Office:
(c). Citizenship:
(d). Title of Class of Securities:
(e). CUSIP Number:
Item 3. Not Applicable.
Item 4. Ownership.
The information in items 1 and 5 through 11 on the cover
pages (page 2) on Schedule 13G Amendment No. 2 is hereby
incorporated by reference.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to
be the beneficial owner of more than five percent of the
class of securities, check the following [X].
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person:
In October 2003, the 21,344 shares held by S.R. One
International B.V. (NETH) were transferred to S.R. One,
Limited (US).
Item 7. Identification and Classification of Subsidiaries Which
Acquired the Security Being Reported on by the Parent
Holding Company:
Item 8. Identification and Classification of Members of the
Group:
Item 9. Notice of Dissolution of Group:
Item 10. Certification:
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were acquired and are not held for the purpose of or
with the effect of changing or influencing the control
of the issuer of such securities and were not acquired
in connection with or as a participant in any
transaction having such purpose or effect.
Signature:
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in
this statement is true, complete and correct.
GLAXOSMITHKLINE PLC
By: /s/
S.M. Bicknell
Company Secretary
Dated: February 13, 2004